About This Information
This content provides supplementary clinical context for the Renflexis Dosing Calculator. It is intended for healthcare professionals to better understand the tool's outputs, the principles of infliximab-abda administration, and common clinical considerations. This guide is not a substitute for the full Prescribing Information or independent clinical judgment.
Calculator Outputs Explained
The tool provides the following key calculations for a single infusion:
- Total Calculated Dose (mg): The precise dose based on the patient's weight and the selected indication's approved mg/kg recommendation.
- Vials Required: The total number of 100 mg single-dose vials needed to prepare the infusion. This value is always rounded up to the nearest whole vial to ensure the full dose can be administered.
- Dosing Schedule: A summary of the standard induction and maintenance infusion timeline for the chosen condition, as per the FDA label.
How to Use the Calculator
To generate a dosing calculation, follow these simple steps:
- Select Indication: Choose the patient's approved indication from the dropdown menu.
- Enter Patient Weight: Input the patient's current body weight.
- Choose Weight Unit: Specify whether the weight is in kilograms (kg) or pounds (lbs). The tool automatically converts lbs to kg to perform the calculation. The results update instantly.
Dosing Overview
Renflexis (infliximab-abda) is a tumor necrosis factor (TNF) blocker administered by intravenous infusion. Dosing is weight-based and follows a standard induction and maintenance schedule.
- Standard Dose: 5 mg/kg is the standard dose for most indications. For Rheumatoid Arthritis, the starting dose is 3 mg/kg, administered in combination with methotrexate.
- Induction Phase: The initial loading-dose schedule for all listed indications consists of infusions at Week 0, Week 2, and Week 6.
- Maintenance Phase: Following induction, maintenance infusions are typically given every 8 weeks. Key exceptions include Ankylosing Spondylitis (every 6 weeks) and Rheumatoid Arthritis, where the dose may be increased or the interval shortened to every 4 weeks based on clinical response.
Switching from a Reference Product
Patients may be switched from a reference infliximab product to Renflexis. When transitioning, the first dose of Renflexis should be administered at the time the next scheduled dose of the reference product was due. No re-induction is necessary. As with any change in therapy, monitor patients for continued efficacy and safety.
Missed Dose Protocol
If a patient misses a scheduled maintenance infusion, the appropriate course of action depends on clinical context and the length of the delay. Consult the full Prescribing Information for guidance. If a significant period has passed since the last dose, re-initiation of the induction schedule (Weeks 0, 2, and 6) may be considered to re-establish therapeutic levels.
Safety Alerts
Renflexis carries a boxed warning for increased risk of serious infections (including tuberculosis, bacterial sepsis, and invasive fungal infections) and malignancies (including lymphoma). Patients should be tested for latent tuberculosis before initiating therapy and monitored closely for signs of infection during and after treatment. Always refer to the latest Prescribing Information for a complete list of warnings, precautions, and contraindications.
Frequently Asked Questions
How does the calculator handle dose rounding for vials?
The calculator determines the total mg dose and then calculates the number of 100 mg vials needed by rounding up to the nearest whole number. This ensures that enough drug is available for reconstitution to administer the full calculated dose.
Can I use this calculator for other infliximab products like Remicade® or Inflectra®?
No. This tool is validated only for Renflexis (infliximab-abda). While dosing may be similar, you must always consult the specific Prescribing Information for the product being administered.
Does the calculator account for dose escalation in IBD?
The calculator is based on standard FDA-approved starting doses (5 mg/kg). Dose escalation (e.g., to 10 mg/kg) is a clinical decision based on patient response and is not a function of this tool.
Why is the maintenance schedule different for Ankylosing Spondylitis?
The approved maintenance dosing interval for Ankylosing Spondylitis (every 6 weeks) is shorter than for most other indications (every 8 weeks) based on evidence from its pivotal clinical trials.
What is the recommended infusion time for Renflexis?
The infusion should be administered intravenously over a period of not less than 2 hours. A shorter infusion time may be considered for select adult patients after they have tolerated initial infusions. Please see the full prescribing information for details.
Is the pediatric dosing for IBD different from the adult dose?
No, for pediatric patients (≥6 years) with moderate to severe Crohn's Disease or Ulcerative Colitis, the recommended dose is the same as for adults: 5 mg/kg.
References
- RENFLEXIS® (infliximab-abda) Prescribing Information. Organon LLC. Available at: organon.com
- U.S. Food and Drug Administration (FDA). Drugs@FDA: RENFLEXIS. Available at: accessdata.fda.gov
- Organon Pro: RENFLEXIS® Professional Resources. Available at: organonpro.com
- Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113(4):481-517. Available at: journals.lww.com
